secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001171843-24-002784
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009
--------------------------------------------------------------------------------

- Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.
- Cash and marketable securities $156.3M at March 31, 2024; cash runway into late 2026.
- FDA Fast Track for CTX-009 in BTC; COMPANION-002 enrollment to complete mid-2024, data Q1 2025.
- Stage 1 of COMPANION-003 (CRC) enrollment complete; top-line data expected by mid-2024.
- CTX-8371 first patient dosed in April 2024; Phase 2 planned for CTX-471 in melanoma with biomarker.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/0001171843-24-002784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/f8k_051124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer